CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,089,273 | -30.9% | 141,515 | +0.7% | 0.00% | – |
| Q2 2023 | $4,468,085 | -33.5% | 140,550 | -49.0% | 0.00% | -100.0% |
| Q1 2023 | $6,716,421 | -5.2% | 275,376 | +22.6% | 0.00% | 0.0% |
| Q4 2022 | $7,083,001 | +123.1% | 224,572 | +99.9% | 0.00% | – |
| Q3 2022 | $3,175,000 | +436.3% | 112,360 | +401.7% | 0.00% | – |
| Q2 2022 | $592,000 | -74.8% | 22,397 | -66.7% | 0.00% | – |
| Q1 2022 | $2,352,000 | -5.8% | 67,190 | -12.8% | 0.00% | – |
| Q4 2021 | $2,497,000 | +137.4% | 77,018 | +116.0% | 0.00% | – |
| Q3 2021 | $1,052,000 | +691.0% | 35,655 | +587.1% | 0.00% | – |
| Q2 2021 | $133,000 | -35.4% | 5,189 | -65.4% | 0.00% | – |
| Q1 2021 | $206,000 | +20500.0% | 15,006 | +31162.5% | 0.00% | – |
| Q4 2020 | $1,000 | – | 48 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |